IBM Halting Sales of AI Tool; Bad News for Drug Discovery Software Is Watson’s Latest Retreat

☞ | View the full content of this post. Exclusively available to ASQ Members.

By Casey Ross

Citing lackluster financial performance, IBM is halting development and sales of a product that uses its Watson artificial intelligence software to help pharmaceutical companies discover new drugs, according to a person familiar with the company’s internal decision-making.

The decision to shut down sales of Watson for Drug Discovery marks the highest-profile retreat in the company’s effort to apply artificial intelligence to various areas of healthcare. Last year, the company scaled back on the hospital

☞ | View the full content of this post. Exclusively available to ASQ Members.

Leave a Comment

Your email address will not be published. Required fields are marked *